Emerging drugs for hyperphosphatemia

Expert Opinion on Emerging Drugs

Volumn 12, Issue 3, 2007, Pages 355-365

  Bellinghieri, Guido ^a   Santoro, Domenico ^a   Savica, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Dialysis; Hyperphosphatemia; Phosphate binder; Vascular calcification

Indexed keywords

ALPHAREN; ALUMINUM CARBONATE; ALUMINUM HYDROXIDE; ALUMINUM SALT; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM DERIVATIVE; CITRATE CALCIUM; COLESTILAN; ILY 101; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; PHOSPHATE BINDING AGENT; RENAZORB; SBR 759; SEBOREN; SEVELAMER; UNCLASSIFIED DRUG; ZERENEX; CALCIUM PHOSPHATE; CHELATING AGENT; LANTHANUM; NEW DRUG; PHOSPHATE; POLYAMINE;

ABDOMINAL PAIN; BLOOD VESSEL CALCIFICATION; BONE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM; CHRONIC KIDNEY FAILURE; CORRELATION ANALYSIS; DIALYSIS; DIARRHEA; DIETARY INTAKE; DRUG BIOAVAILABILITY; DRUG STRUCTURE; HEMATOPOIETIC CELL; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LONG TERM EXPOSURE; METASTASIS; MORBIDITY; MORTALITY; NAUSEA; PHOSPHATE BLOOD LEVEL; PLEIOTROPY; REVIEW; RISK FACTOR; TISSUE DISTRIBUTION; UREMIA; VOMITING; ANIMAL; ATHEROSCLEROSIS; BLOOD; CALCINOSIS; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; METABOLISM; RENAL REPLACEMENT THERAPY; SALIVA;

ANIMALS; ATHEROSCLEROSIS; CALCINOSIS; CALCIUM PHOSPHATES; CHELATING AGENTS; DRUGS, INVESTIGATIONAL; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; PHOSPHATES; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; RENAL DIALYSIS; SALIVA; UREMIA;

EID: 34748918903     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.3.355     Document Type: Review

References (57)

1. GUÉRIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. (2000) 15:1014-1021.
2. GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2000) 342:1478-1483.
3. MOE SM, O'NEILL KD, RESLEROVA M, FINEBERG N, PERSOHN S, MEYER CA: Natural history of vascular calcification in dialysis and transplant patients. Nephrol. Dial. Transplant. (2004) 19(9):2387-2393.
4. MELAMED ML, EUSTACE JA, PLANTINGA L et al.: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. (2006) 70(2):351-357.
5. BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. (2000) 35:1226-1237.
6. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. (1998) 31:601-617.
7. EKNOYAN G, LEVIN NW: Impact of the new K/DOQI guidelines. Blood Purif. (2002) 20(1):103-108.
8. NOORDZI JM, KOREVAAR JC, BOESCHOTEN EW, DEKKER FW, BOS WJ, KREDIET RT: Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The kidney disease outcomes quality initiative (K/DOQI) Guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am. J. Kidney Dis. (2005) 46(5):925-932.
9. BLOCK GA, KLASSEN PS, LAZARUS JM, OFSTHUN N, LOWRIE EG, CHERTOW GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. (2004) 15(8):2208-2218.
10. KOPPLE JD: National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am. J. Kidney Dis. (2001) 37(1 Suppl. 2):S66-S70.
11. GOTCH FA, PANLILIO F et al.: A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif. (2003) 21(1):51-57.
12. TOUSSAINT N, BODDINGTON J, SIMMONDS R, WALDRON C, SOMERVILLE C, AGAR J: Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis. Hemodial. Int. (2006) 10(3):280-6.
13. DELMEZ JA, SLATOPOLSKY E, MARTIN KJ, GEARING BN, HARTER HR: Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis. Kidney Int. (1982) 21(6):862-867.
14. ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis encephalopathy syndrome. Possible aluminum intoxication. N. Engl. J. Med. (1976) 294(4):184-188.
15. MOLONY DA, MURTHY B: Accumulation of metals and minerals from phosphate binders. Blood Purif. (2005) 23(Suppl. 1):2-11 (Review).
16. WILHELM M, JAGER DE, OHNESORGE FK: Aluminum toxicokinetics. Pharmacol. Toxicol. (1990) 66(1):4-9 (Review).
17. MOLITORIS BA, FROMENT DH, MACKENZIE TA, HUFFER WH, ALFREY AC: Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int. (1989) 36(6):949-953.
18. SLATOPOLSKY E, WEERTS C, LOPEZ-HILKER S et al.: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. (1986) 315:157-161.
19. SLATOPOLSKY E, WEERTS C, NORWOOD K et al.: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int. (1989) 36(5):897-903.
20. LONDON GM, GUERIN AP, MARCHAIS SJ, METIVIER F, PANNIER B, ADDA H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. (2003) 18(9):1731-1740.
21. SALUSKY IB, KUIZON BD, BELIN TR et al.: Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int. (1998) 54(3):907-914.
22. KURZ P, MONIER-FAUGERE MC, BOGNAR B et al.: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. (1994) 46(3):855-861
23. LONDON GM, MARTY C, MARCHAIS SJ, GUERIN AP, METIVIER F, DE VERNEJOUL MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. (2004) 15(7):1943-1951.
24. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practisce guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. (2003) 42(Suppl. 3):S12-S28.
25. MILLINER DS, ZINSMEISTER AR, LIEBERMAN E, LANDING B: Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. (1990) 38(5):931-936.
26. EMMETT M, SIRMON M, KIRKPATRICK W, NOLAN CR, SCHMITT GW, CLEVELAND MVB: Calcium acetate control of serum phosphorus in hemodialysis patients. Am. J. Kidney Dis. (1991) 5:544-550.
27. NOLAN CR, CALIFANO JR, BUTZIN CA: Influence of calcium acetate or calcium citrate on intestinal aluminum absorption. Kidney Int. (1990) 38(5):937-941.
28. GUILLOT AP, HOOD VL, RUNGE CF, GENNARI FJ: The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron (1982) 30(2):114-117.
29. DELMEZ JA, KELBER J, NORWORD KY, GILES KS, SLATOPOLSKY E: Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. (1996) 49(0:163-167.
30. BURKE SK, SLATOPOLSKY E, GOLDBERG DI: Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol. Dial. Transplant. (1997) 12:1640-1644.
31. GOLDBERG DI, DILLON MA, SLATOPOLSKY E et al.: Effect of Renagel, a non absorbed, calcium and aluminum free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end stage renal disease patients. Nephrol. Dial. Transplant. (1998) 13:2303-2310.
32. BLEYER AJ, BURKE SK, DILLON M et al.: A comparison of the calcium-free phosphate binder sevelamer hydrocloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. (1999) 33:694-701.
33. CHERTOW GM, BURKE SK, DILLON MA, SLATOPOLSKY E: For the Renagel Study Group. Long-term effects of sevelamer hydrocloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol. Dial. Transplant. (1999) 14:2907-2914.
34. QUNIBI WY, HOOTKINS RE, MCDOWELL LL et al.: Treatment of hyperphosphatemia in hemodialysis patients: the calcium acetate renagel evaluation (CARE study). Kidney Int. (2004) 65(5):1914-1926.
35. COLLINS AJ, ST PETER WL, DALLESKA FW, EBBEN JP, MA JZ: Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin. Nephrol. (2000) 54(4):334-341 (Review).
36. NAGANO N, MIYATA S, ABE M, WAKITA S, KOBAYASHI N, WADA M: Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nephrol. Dial. Transplant. (2006) 21:634-643.
37. RAGGI P: Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients. Clin. Nephrol. (2000) 54:325-333.
38. RAGGI P: Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease. Nephrol. Dial. Transplant. (2002) 17:332-335.
39. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62:245-252.
40. BLOCK GA, SPIEGEL DM, EHRLICH J et al.: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. (2005) 68(4):1815-1824.
41. BLOCK GA, RAGGI P, BELLASI A, KOOIENGA L, SPIEGEL DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. (2007) 71(5):438-441.
42. FERRAMOSCA E, BURKE S, CHASAN-TABER S, RATTI C, CHERTOW GM, RAGGI P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am. Heart J. (2005) 149(5):820-825.
43. LOCATELLI F, D'AMICO M, PONTORIERO G: Lanthanum carbonate. Drugs (2003) 6: 688-695.
44. PENNICK M, DENNIS K, DAMMENT SJ: Absolute bioavailability and disposition of Lanthanum in healthy human subjects administered lanthanum carbonate. J. Clin. Pharmacol. (2006) 46(7):738-746.
45. JOY MS, FINN WF: Randomized, double-blind, placebocontrolled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for die treatment of hyperphosphatemia. Am. J. Kidney Dis. (2003) 42:96-107.
46. HUTCHISON AJ, MAES B, VANWALLEGHEM J et al.: Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin. Pract. (2006) 102(2):C61-C71.
47. FREEMONT AJ, HOYLAND JA, DENTON J; LANTHANUM CARBONATE SPD405-303 STUDY GROUP: The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin. Nephrol. (2005) 64(6):428-437.
48. LACOUR B, LUCAS A, AUCHERE D, RUELLAN N, DE SERRE PATEY NM, DRUEKE TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. (2005) 67(3): 1062-1069.
49. SLATOPOLSKY E, LIAPIS H, FINCH J: Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. (2005) 68(6):2809-2813.
50. YANG Z, SCHRYVERS D, ROELS F, D'HAESE PC, DE BROE ME: Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J. Microsc. (2006) 223(Part2):133-139.
51. BEN-DOV IZ, PAPPO O, SKLAIR-LEVY M et al.: Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats. Nephrol. Dial. Transplant. (2007) 22(2):362-368.
52. LAC G: Saliva assays in clinical and research biology. Pathol. Biol. (2001) 49:660-667.
53. SAVICA V, CALO LA, CALDARERA R et al.: Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. Nephron Physiol. (2007) 105(3):52-55.
54. DATE T, SHIGEMATSU T, KAWASHITA Y, SATAKE N, MORITA K: Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol. Dial. Transplant. (2003) 18(Suppl. 3):90-93.
55. HERGESELL O, RITZ E: Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol. Dial. Transplant. (1999) 14:863-867.
56. KUHLMANN MK: Practical approaches to management of hyperphosphatemia: can we improve the current situation? Blood Purif. (2007) 25(0:120-124.
57. YOUNG EW, ALBERT JM, SATAYATHUM S et al.: Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. (2005) 67(3): 1179-1187.